A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

NCT04980222 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Glofitamab
DRUG: Tocilizumab
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: Rituximab
DRUG: Cyclophosphamide

Sponsor

Hoffmann-La Roche